logo
  

DSMB Recommends Continuation Of RedHill Biopharma's Phase 2/3 Covid Study Of Opaganib

RedHill Biopharma Ltd. (RDHL) said the mid/late stage study of its Covid-19 drug candidate, Opaganib passed fourth review by an independent Data Safety Monitoring Board (DSMB).

Following the analysis of safety data from the first 255 patients of total 380, treated with Opaganib for 14 days, the company received unanimous recommendation from DSMB to continue the Phase 2/3 study of orally-administered opaganib in severe Covid-19 pneumonia.

Redhill said a 464-patient global Phase 2/3 study of Opaganib in Covid-19 is going on.

"Adding together the positive Phase 2 data, the successful DSMB futility reviews and the outcomes from compassionate use of opaganib, we look forward with optimism to the reporting of top-line data from the Phase 2/3 study, which will provide the clearest indication to date of opaganib's promise in treating COVID-19," Mark L. Levitt, Medical Director at RedHill, said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors will start replacing defective battery modules in Chevrolet Bolt EVs and EUVs with new modules. The replacement battery modules will be shipped to dealers as soon as mid-October, the automaker said in a statement. CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million...
Follow RTT